arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

iBio, Inc.

IBIO
$1.39 ▼ -0.01 (-0.71%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

iBio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $14.6M
Dividend Yield
Revenue Growth 77.8%
Op. Margin None
ROIC -98.8%
FCF / Share $-1.46
Trailing P/E
Price / Book 1.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$400.00K
↑ +77.8%
Net Income Profit after all expenses
$-18.38M
↑ +26.2%
FCF / Share Free cash flow per share
$-1.46
↑ +70.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Financial Health
14
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 64 quarters